Cargando…

Cost-Effectiveness Analysis of Three Diagnostic Strategies for the Detection of EGFR Mutation in Advanced Non-Small Cell Lung Cancer

BACKGROUND: In non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) mutation testing of tumor tissue should be conducted at diagnosis. Alternatively, circulating tumor DNA can be used to detect EGFR mutation. We compared the cost and clinical effect of three strategies accordi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Sun Mi, Lee, Hye Sun, Jeon, Soyoung, Kim, Yoonjung, Kong, Sun-Young, Lee, Jin Kyung, Lee, Kyung-A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Laboratory Medicine 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345179/ https://www.ncbi.nlm.nih.gov/pubmed/37387493 http://dx.doi.org/10.3343/alm.2023.43.6.605

Ejemplares similares

A Comparative Study for Detection of EGFR Mutations in Plasma Cell-Free DNA in Korean Clinical Diagnostic Laboratories
por: Kim, Yoonjung, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer
por: Jang, Jaehyeok, et al.
Publicado: (2023)

Selecting short length nucleic acids localized in exosomes improves plasma EGFR mutation detection in NSCLC patients
por: Kim, Yoonjung, et al.
Publicado: (2019)

Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non‐small cell lung cancer patients
por: Kim, Insu, et al.
Publicado: (2019)

Spectrum of EGFR Gene Copy Number Changes and KRAS Gene Mutation Status in Korean Triple Negative Breast Cancer Patients
por: Kim, Yoonjung, et al.
Publicado: (2013)

Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer
por: Kim, Boyeon, et al.
Publicado: (2022)

Detection of EGFR-SEPT14 fusion in cell-free DNA of a patient with advanced gastric cancer: A case report
por: Kim, Boyeon, et al.
Publicado: (2021)

Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy
por: Kim, Yoonjung, et al.
Publicado: (2021)

Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer
por: Lee, Sangah, et al.
Publicado: (2021)

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
por: Low, Jia Li, et al.
Publicado: (2023)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
por: Lee, Ki-Chang, et al.
Publicado: (2021)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
por: Lee, Chaelin, et al.
Publicado: (2022)

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
por: Lee, Jiyun, et al.
Publicado: (2019)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
por: Byeon, Seonggyu, et al.
Publicado: (2019)

Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping
por: Kim, Hye-Ryoun, et al.
Publicado: (2013)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
por: Cho, Jaeyoung, et al.
Publicado: (2016)

Frequency and Clinical Characteristics of Unselected Korean Gastric Cancer Patients with a Germline CDH1 V832M Mutation
por: Shin, Saeam, et al.
Publicado: (2020)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation
por: Cho, Min-Sun, et al.
Publicado: (2020)

Diagnostic and Predictive Values of (18)F-FDG PET/CT Metabolic Parameters in EGFR-Mutated Advanced Lung Adenocarcinoma
por: Hong, Il Ki, et al.
Publicado: (2020)

Evaluation of Three Automated Nucleic Acid Extraction Systems for Identification of Respiratory Viruses in Clinical Specimens by Multiplex Real-Time PCR
por: Kim, Yoonjung, et al.
Publicado: (2014)

Effect of Walking Steps Measured by a Wearable Activity Tracker on Improving Components of Metabolic Syndrome: A Prospective Study
por: Park, Jae-Min, et al.
Publicado: (2022)

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
por: Lee, Ji Yun, et al.
Publicado: (2016)

Effects of Different Centrifugation Protocols on the Detection of EGFR Mutations in Plasma Cell-Free DNA
por: Shin, Kyung-Hwa, et al.
Publicado: (2022)

LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
por: Cho, Jung Hee, et al.
Publicado: (2022)

Erratum to “Partial Gene Deletions of PMP22 Causing Hereditary Neuropathy with Liability to Pressure Palsies”
por: Cho, Sun-Mi, et al.
Publicado: (2015)

Partial Gene Deletions of PMP22 Causing Hereditary Neuropathy with Liability to Pressure Palsies
por: Cho, Sun-Mi, et al.
Publicado: (2014)

EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital
por: Choi, Yoon-La, et al.
Publicado: (2013)

Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation
por: Li, Yan, et al.
Publicado: (2016)

EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis
por: You, Joyce H. S., et al.
Publicado: (2021)

Treatment strategy of EGFR-mutated non-small cell lung cancer
por: Tanaka, Fumihiro, et al.
Publicado: (2022)

Detection of EGFR Mutations Using Bronchial Washing-Derived Extracellular Vesicles in Patients with Non-Small-Cell Lung Carcinoma
por: Park, Juhee, et al.
Publicado: (2020)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study
por: Yu, Xiaoqing, et al.
Publicado: (2022)

Optimal sequencing strategies in the treatment of EGFR mutation–positive non–small cell lung cancer: Clinical benefits and cost-effectiveness
por: Hirsh, Vera, et al.
Publicado: (2020)

Targeted sequencing with enrichment PCR: a novel diagnostic method for the detection of EGFR mutations
por: Kang, Suki, et al.
Publicado: (2015)

Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer
por: Yeo, Min-Kyung, et al.
Publicado: (2022)

Cutoff Points of Waist Circumference for Predicting Incident Non-Alcoholic Fatty Liver Disease in Middle-Aged and Older Korean Adults
por: Lee, Jun-Hyuk, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_khc9v5p4n48k720ojpicrp9du6